Seeking Alpha

Sarepta jumps after WMS presentation shows weak dystrophin data for drisapersen

  • Sarepta Therapeutics (SRPT +6.2%) trades notably higher in morning action.
  • The shares look to be getting a boost from drisapersen (RNA, GSK) data presented Wednesday at the World Muscle Society.
  • Ultimately, the dystrophin production data for drisapersen (see here) was weak — only 12-29% of patients realized an increase in the precursor to dystrophin.
  • Baird maintains a Buy on SRPT. Price target is $63.
  • RBC is apparently out incrementally more positive on SRPT as well.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: